Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
109 studies found for:    daclatasvir
Show Display Options
Rank Status Study
1 Not yet recruiting Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
Condition: Chronic Hepatitis C
Intervention: Drug: Daclatasvir and Asunaprevir
2 Completed
Has Results
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Darunavir;   Drug: Ritonavir;   Drug: Lopinavir/Ritonavir
3 Completed
Has Results
Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
Condition: Hepatitis C
Intervention: Drug: Daclatasvir
4 Active, not recruiting A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   Genotype 3 Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530;   Drug: sofosbuvir;   Drug: daclatasvir
5 Active, not recruiting An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir;   Drug: Daclatasvir;   Drug: Sofosbuvir
6 Completed A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir;   Drug: Daclatasvir;   Drug: Ribavirin;   Drug: Cyclosporine;   Drug: Tacrolimus
7 Unknown  Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Condition: Hepatitis C Virus Genotype 4 Infection
Interventions: Drug: Asunaprevir;   Drug: Daclatasvir;   Drug: Ribavirin;   Drug: Pegylated Interferon alpha-2a
8 Recruiting Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)
Condition: Hepatitis C, Chronic
Interventions: Drug: Daclatasvir + Sofosbuvir;   Drug: Simeprevir + Sofosbuvir
9 Completed
Has Results
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir
10 Completed
Has Results
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
Condition: Hepatitis C Virus
Interventions: Drug: Daclatasvir;   Drug: Simeprevir;   Drug: Ribavirin
11 Completed Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmacuetical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
Condition: Healthy
Interventions: Drug: Daclatasvir Zeta;   Drug: Clatazev
12 Completed
Has Results
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir
13 Completed A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
Conditions: Hepatitis C;   HIV
Interventions: Drug: Daclatasvir;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Cobicistat
14 Completed A Drug-drug Interaction Study Between Daclatasvir and Metformin
Conditions: Hepatitis C;   Diabetes Mellitus;   Insulin Resistance
Interventions: Drug: Daclatasvir;   Drug: Metformin
15 Withdrawn A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
16 Withdrawn Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
Condition: Hepatitis C
Interventions: Drug: Peginterferon alfa 2a;   Drug: Ribavirin;   Drug: Placebo matching Daclatasvir;   Drug: Daclatasvir
17 Completed A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir
Condition: Hepatitis C Infection
Interventions: Drug: Daclatasvir;   Drug: Asunaprevir
18 Completed Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
Conditions: Hepatitis C;   Cirrhosis
Interventions: Drug: Sofosbuvir;   Drug: Daclatasvir;   Drug: Ribavirin
19 Completed Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Pegylated interferon lambda (pegIFNλ);   Biological: Pegylated interferon alfa-2a (pegIFNα-2a);   Drug: Ribavirin;   Drug: Daclatasvir;   Drug: Placebo matching Daclatasvir
20 Completed A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir;   Drug: Daclatasvir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years